# First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas

> **NCT04358458** · PHASE1,PHASE2 · TERMINATED · sponsor: **Genmab** · enrollment: 46 (actual)

## Conditions studied

- Diffuse Large B-cell Lymphoma
- Follicular Lymphoma
- Marginal Zone Lymphoma
- Small Lymphocytic Lymphoma
- Mantle Cell Lymphoma
- Chronic Lymphocytic Leukemia
- High-grade B-cell Lymphoma
- Primary Mediastinal Large B-cell Lymphoma

## Interventions

- **BIOLOGICAL:** GEN3009
- **BIOLOGICAL:** Epcoritamab

## Key facts

- **NCT ID:** NCT04358458
- **Lead sponsor:** Genmab
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-03-13
- **Primary completion:** 2022-11-21
- **Final completion:** 2023-07-28
- **Target enrollment:** 46 (ACTUAL)
- **Why stopped:** Due to strategic evaluation of GEN3009 within context of Genmab's portfolio, decision not based on any safety or regulatory concerns.
- **Last updated:** 2024-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04358458

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04358458, "First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphomas". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04358458. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*